NEW YORK, Sept. 13, 2018 /PRNewswire/ -- Bernstein Liebhard
LLP, a nationally acclaimed investor rights law firm, is
investigating potential securities fraud claims on behalf of
shareholders of Alnylam Pharmaceuticals, Inc. ("Alnylam" or the
"Company") (NASDAQ: ALNY) resulting from allegations that Alnylam
and/or its executives may have issued materially misleading
business information to the investing public.
If you purchased Alnylam securities, and/or would like to
discuss your legal rights and options, please visit Alnylam
Shareholder Investigation or contact Daniel
Sadeh toll free at (877) 779-1414 or
dsadeh@bernlieb.com.
On September 12, 2018, Nomura/Instinet analyst
Christopher Marai stated that a review document released by the
U.S. Food and Drug Administration's ("FDA") Center for Drug
Evaluation and Research "highlights greater risk" with respect to
certain trials of Alnylams' ONPATTRO (patisiran) lipid complex
injection, as well as "a limited market opportunity in
TTRcardiomyopathy, and a potential platform safety
risk." Specifically, Marai asserted that "[t]he document
highlights FDA reviewers' concerns over cardiac deaths in patients
treated with ONPATTRO and suggests that the drug should be limited
to patients with polyneuropathy only (i.e., not
patients with cardiac manifestations and polyneuropathy).
Furthermore, we believe some comments on the lack of cardiac
efficacy call into question claims made by [Alnylam] in this
regard."
On this news, Alnylam stock fell $5.60 per share, or over 5%, from its previous
closing price to close at $94.75 per
share on September 12, 2018, damaging
investors.
If you purchased Alnylam securities, and/or would like to
discuss your legal rights and options, please visit
https://www.bernlieb.com/cases/alnylam-pharmaceuticals-inc-alny-lawsuit-class-action-fraud-stock-82/
or contact Daniel Sadeh toll free at
(877) 779-1414 or dsadeh@bernlieb.com.
Since 1993, Bernstein Liebhard LLP has recovered over
$3.5 billion for its clients. In
addition to representing individual investors, the Firm has been
retained by some of the largest public and private pension funds in
the country to monitor their assets and pursue litigation on their
behalf. As a result of its success litigating hundreds of lawsuits
and class actions, the Firm has been named to The National Law
Journal's "Plaintiffs' Hot List" thirteen times and listed in
The Legal 500 for ten consecutive years.
ATTORNEY ADVERTISING. © 2018 Bernstein Liebhard LLP. The law
firm responsible for this advertisement is Bernstein Liebhard LLP,
10 East 40th Street, New York, New
York 10016, (212) 779-1414. The lawyer responsible for this
advertisement in the State of
Connecticut is Michael S. Bigin. Prior results do not
guarantee or predict a similar outcome with respect to any future
matter.
Contact Information
Daniel Sadeh
Bernstein Liebhard LLP
http://www.bernlieb.com
(877) 779-1414
dsadeh@bernlieb.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/alnylam-investigation-bernstein-liebhard-llp-announces-investigation-of-alnylam-pharmaceuticals-inc---alny-300712468.html
SOURCE Bernstein Liebhard LLP